BR112014007223A2 - derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos - Google Patents

derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos

Info

Publication number
BR112014007223A2
BR112014007223A2 BR112014007223A BR112014007223A BR112014007223A2 BR 112014007223 A2 BR112014007223 A2 BR 112014007223A2 BR 112014007223 A BR112014007223 A BR 112014007223A BR 112014007223 A BR112014007223 A BR 112014007223A BR 112014007223 A2 BR112014007223 A2 BR 112014007223A2
Authority
BR
Brazil
Prior art keywords
processes
preparation
estra
tetraene
preparing medicaments
Prior art date
Application number
BR112014007223A
Other languages
English (en)
Inventor
Rotgeri Andrea
Hartung Ingo
Gashaw Isabella
Busemann Matthias
Barak Naomi
Martin Fischer Oliver
Marquardt Tobias
Bothe Ulrich
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014007223(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of BR112014007223A2 publication Critical patent/BR112014007223A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos". a presente invenção refere-se a inibidores de akr1c3 e a processos para sua preparação, ao uso dos mesmos para o tratamento e/ou profilaxia de doenças e também ao uso dos mesmos para preparar medicamentos para o tratamento e/ou profilaxia de doenças, em particular, distúrbios de sangramento e endometriose.
BR112014007223A 2011-09-29 2012-09-24 derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos BR112014007223A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011083725A DE102011083725A1 (de) 2011-09-29 2011-09-29 Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
PCT/EP2012/068803 WO2013045407A1 (de) 2011-09-29 2012-09-24 Estra-1,3,5(10),16-tetraen-3-carboxamid-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
BR112014007223A2 true BR112014007223A2 (pt) 2017-04-04

Family

ID=46963705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007223A BR112014007223A2 (pt) 2011-09-29 2012-09-24 derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos

Country Status (42)

Country Link
US (1) US9487554B2 (pt)
EP (1) EP2760878B1 (pt)
JP (1) JP5791810B2 (pt)
KR (1) KR20140069013A (pt)
CN (1) CN103827133B (pt)
AP (1) AP2014007598A0 (pt)
AR (1) AR088180A1 (pt)
AU (1) AU2012314627B2 (pt)
BR (1) BR112014007223A2 (pt)
CA (1) CA2850047C (pt)
CL (1) CL2014000775A1 (pt)
CO (1) CO6920294A2 (pt)
CR (1) CR20140144A (pt)
CU (1) CU20140037A7 (pt)
CY (1) CY1117123T1 (pt)
DE (1) DE102011083725A1 (pt)
DK (1) DK2760878T3 (pt)
DO (1) DOP2014000059A (pt)
EA (1) EA025518B9 (pt)
EC (1) ECSP14013275A (pt)
ES (1) ES2560257T3 (pt)
GT (1) GT201400059A (pt)
HK (1) HK1197414A1 (pt)
HR (1) HRP20160050T1 (pt)
HU (1) HUE026645T2 (pt)
IL (1) IL231755A (pt)
JO (1) JO3122B1 (pt)
MA (1) MA35455B1 (pt)
MX (1) MX2014003823A (pt)
MY (1) MY175804A (pt)
PE (1) PE20141554A1 (pt)
PL (1) PL2760878T3 (pt)
PT (1) PT2760878E (pt)
RS (1) RS54521B1 (pt)
SG (1) SG11201400144SA (pt)
SI (1) SI2760878T1 (pt)
TN (1) TN2014000131A1 (pt)
TW (1) TWI537284B (pt)
UA (1) UA107550C2 (pt)
UY (1) UY34356A (pt)
WO (1) WO2013045407A1 (pt)
ZA (1) ZA201401568B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878485A1 (en) 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
AP3826A (en) * 2013-02-21 2016-09-30 Bayer Pharma Aktiengellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
EP3194419B1 (en) * 2014-09-11 2018-09-05 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) * 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3555067A1 (en) 2016-12-19 2019-10-23 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
WO2018114677A2 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN108503695B (zh) * 2018-03-09 2021-06-08 南方医科大学南方医院 基于GnRH多肽衍生物的示踪剂及其制备方法和应用
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN113683648A (zh) * 2021-08-26 2021-11-23 上海皓鸿生物医药科技有限公司 一种2’-氟-2’-脱氧尿苷的合成方法及其中间体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632003A (en) 1985-07-15 1986-12-30 Kopp William L Musical instrument sound quality enhancement device
GB2265624B (en) * 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
HUP0101809A3 (en) 1998-03-11 2002-07-29 Endorech Inc Sainte Foy Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use
CA2558014A1 (en) * 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
JP5264760B2 (ja) * 2006-11-30 2013-08-14 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング １７β−ＨＳＤインヒビターとしての置換エストラトリエン誘導体
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
SI2563803T1 (sl) 2010-04-27 2016-06-30 Pharma Mar S.A. Na položaju 7 (8) nenasičeni steroidni lakton proti raku

Also Published As

Publication number Publication date
MA35455B1 (fr) 2014-09-01
JP5791810B2 (ja) 2015-10-07
NZ622081A (en) 2015-10-30
CN103827133A (zh) 2014-05-28
US9487554B2 (en) 2016-11-08
TN2014000131A1 (en) 2015-07-01
TWI537284B (zh) 2016-06-11
SG11201400144SA (en) 2014-05-29
US20140249119A1 (en) 2014-09-04
ECSP14013275A (es) 2014-04-30
DK2760878T3 (en) 2016-01-25
CL2014000775A1 (es) 2014-08-18
GT201400059A (es) 2015-02-17
PL2760878T3 (pl) 2016-04-29
IL231755A (en) 2016-06-30
CA2850047C (en) 2016-03-29
HUE026645T2 (en) 2016-07-28
CO6920294A2 (es) 2014-04-10
TW201317253A (zh) 2013-05-01
EP2760878A1 (de) 2014-08-06
EA201490653A1 (ru) 2014-09-30
HRP20160050T1 (hr) 2016-02-12
SI2760878T1 (sl) 2016-02-29
RS54521B1 (en) 2016-06-30
AP2014007598A0 (en) 2014-04-30
JO3122B1 (ar) 2017-09-20
PT2760878E (pt) 2016-02-26
ZA201401568B (en) 2016-11-30
WO2013045407A1 (de) 2013-04-04
AU2012314627A1 (en) 2014-04-10
PE20141554A1 (es) 2014-10-24
CY1117123T1 (el) 2017-04-05
EA025518B1 (ru) 2016-12-30
EA025518B9 (ru) 2017-10-31
KR20140069013A (ko) 2014-06-09
CA2850047A1 (en) 2013-04-04
DE102011083725A1 (de) 2013-04-04
HK1197414A1 (zh) 2015-01-16
CR20140144A (es) 2014-05-16
UY34356A (es) 2013-04-30
ES2560257T3 (es) 2016-02-18
CN103827133B (zh) 2015-11-25
EP2760878B1 (de) 2015-10-28
DOP2014000059A (es) 2014-06-15
CU20140037A7 (es) 2014-07-30
JP2014527994A (ja) 2014-10-23
AU2012314627B2 (en) 2016-08-18
MX2014003823A (es) 2014-06-04
UA107550C2 (uk) 2015-01-12
AR088180A1 (es) 2014-05-14
MY175804A (en) 2020-07-09

Similar Documents

Publication Publication Date Title
BR112014007223A2 (pt) derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112014015845A8 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015014372A2 (pt) inibidores de autotaxina
BR112013029537A2 (pt) derivados de quinazolina para tratamento de infecções virais e outras doenças
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015008447A2 (pt) métodos para tratar câncer
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112015018071A2 (pt) estra-1,3,5(10),16-tetraeno-3-carboxamidas
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
BR112015000443A2 (pt) derivados de estra-1,3,5(10),16-tetraeno 3-substituídos, processo para a sua produção, preparações farmacêuticas que contêm os mesmos, bem como seu uso para a produção de medicamentos
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112014002674A2 (pt) 3-(bifenil-3-il)-4-hidróxi-8-metóxi-1-azaspiro[4.5]dec-3-en-2-onas substituídas
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
BR112013020702A2 (pt) preparação farmacêutica contendo selenita ou compostos contendo selenita para o tratamento de displasias cervicais ou carcinomas
BR112013029927A2 (pt) "compostos antibióticos, composições farmacêuticas, usos das referidas composições e métodos de produção dos referidos compostos".
BR112015017541A2 (pt) fármaco profilático ou terapêutico para constipação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]